Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Employees - 310, CEO - Ms. Jane Chung R.Ph., Sector - Healthcare, Country - US, Market Cap - 97.86M

Altman ZScore(max is 10): -3.57, Piotroski Score(max is 10): 2, Working Capital: $211417000, Total Assets: $387207000, Retained Earnings: $-786869000, EBIT: -194028000, Total Liabilities: $342606000, Revenue: $62043000

- Current Price $1.16 - Analyst Target Price $5.12